Extended indication Eradicatie van Helicobacter pylori bij een ulcus pepticum.
Therapeutic value No judgement
Total cost 1,704,010.00
Registration phase Clinical trials

Product

Active substance Amoxicilline / omeprazol / rifabutin
Domain Infectious diseases
Main indication Bacterial infections
Extended indication Eradicatie van Helicobacter pylori bij een ulcus pepticum.
Manufacturer RedHill
Mechanism of action Unknown
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Extramural (GVS)
Additional remarks Combinatie van twee antibiotica en een maagzuurremmer.

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity New therapeutical formulation
ATMP Unknown
Expected Registration 2018
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Betreft alternatief voor Panclamox.
Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume 10,000 - 20,981

Market share is generally not included unless otherwise stated.

References GIP databank
Additional remarks 20981 gebruikers Panclamox (alternatief) in 2016.

Expected cost per patient per year

Cost 70.00 - 150.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Additional remarks Beperkte kosten, naar verwachting vergelijkbaar met Panclamox (uitgaande van 7 - 14 dagen, 2x per dag).

Potential total cost per year

Total cost 1,704,010.00

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information